RxDoctor Payments Data

David Cziperle, MD

Vascular Surgery · Lancaster, PANPI 1295797900

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $33,200 of the $36,946 with a category attached, or 89.9%. Mallinckrodt Enterprises LLC accounts for 73.6% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $28,226 and has fallen 99.7% since, to $80 in 2024. Among vascular surgery clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$36,946in general payments, 2019–2025

Across 35 payments — averaging $1055.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Enterprises LLC$27K
  • Mallinckrodt Hospital Products Inc.$8K
  • Davol Inc.$2K
  • Intuitive Surgical$334

What the payments were for

  • Consulting fees$1,4004%
  • Speaking & faculty fees$33,20090%
  • Travel & lodging$1,4224%
  • Food & beverage$9172%
  • Education$70%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,946 in reported general payments places this provider in the 90th percentile of 236 vascular surgery providers in Pennsylvania.

See all vascular surgery providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$79,940
Medicare patients
168
Services billed
347

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gabapentin19$109

Paid to pharmacies, not to this prescriber.

Other vascular surgery in Lancaster

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →